[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT3843759T - Utilização de linfócitos infiltrantes de tumores para tratar doentes com nsclc refratário ao anticorpo anti-pd-1 - Google Patents

Utilização de linfócitos infiltrantes de tumores para tratar doentes com nsclc refratário ao anticorpo anti-pd-1

Info

Publication number
PT3843759T
PT3843759T PT198564338T PT19856433T PT3843759T PT 3843759 T PT3843759 T PT 3843759T PT 198564338 T PT198564338 T PT 198564338T PT 19856433 T PT19856433 T PT 19856433T PT 3843759 T PT3843759 T PT 3843759T
Authority
PT
Portugal
Prior art keywords
antibody
tumor infiltrating
infiltrating lymphocytes
nsclc patients
treating nsclc
Prior art date
Application number
PT198564338T
Other languages
English (en)
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Publication of PT3843759T publication Critical patent/PT3843759T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT198564338T 2018-08-31 2019-09-03 Utilização de linfócitos infiltrantes de tumores para tratar doentes com nsclc refratário ao anticorpo anti-pd-1 PT3843759T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725976P 2018-08-31 2018-08-31
US201862726919P 2018-09-04 2018-09-04

Publications (1)

Publication Number Publication Date
PT3843759T true PT3843759T (pt) 2024-06-18

Family

ID=69701469

Family Applications (1)

Application Number Title Priority Date Filing Date
PT198564338T PT3843759T (pt) 2018-08-31 2019-09-03 Utilização de linfócitos infiltrantes de tumores para tratar doentes com nsclc refratário ao anticorpo anti-pd-1

Country Status (19)

Country Link
US (2) US20220118012A1 (pt)
EP (2) EP3843759B8 (pt)
JP (1) JP2021535128A (pt)
KR (1) KR20210053922A (pt)
CN (1) CN112955160A (pt)
AU (1) AU2019377771A1 (pt)
BR (1) BR112021003491A2 (pt)
CA (1) CA3111210A1 (pt)
DK (1) DK3843759T5 (pt)
ES (1) ES2982415T3 (pt)
FI (1) FI3843759T3 (pt)
HU (1) HUE066849T2 (pt)
IL (1) IL281022A (pt)
MX (1) MX2021002241A (pt)
PL (1) PL3843759T3 (pt)
PT (1) PT3843759T (pt)
SG (1) SG11202101792TA (pt)
TW (1) TW202031273A (pt)
WO (1) WO2020096682A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CA3164986A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
JP2024501452A (ja) * 2020-12-11 2024-01-12 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｂｒａｆ阻害剤及び／またはｍｅｋ阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
NZ257942A (en) 1992-10-23 1996-04-26 Immunex Corp Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
ATE226641T1 (de) 1995-04-08 2002-11-15 Lg Chemical Ltd Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
ES2300113T3 (es) 1996-08-02 2008-06-01 Bristol-Myers Squibb Company Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo.
RU2192281C2 (ru) 1996-10-11 2002-11-10 Бристол-Маерс Сквибб Компани Способы и композиции для иммуномодуляции
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ATE537845T1 (de) 2000-10-31 2012-01-15 Pr Pharmaceuticals Inc Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
EP1525223B1 (en) 2002-06-13 2007-11-21 Crucell Holland B.V. Ox40 (=cd134) receptor agonists and therapeutic use
WO2004010947A2 (en) 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
BRPI0314814C1 (pt) 2002-09-27 2021-07-27 Xencor Inc anticorpo compreendendo uma variante de fc
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2336293B1 (en) 2003-10-08 2016-02-10 Wilson Wolf Manufacturing Corporation Cell culture methods and devices utilizing gas permeable materials
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
CA2561264A1 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN101987870B (zh) 2004-07-15 2013-07-03 赞科股份有限公司 优化的Fc变体
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
EP1814568A4 (en) 2004-10-29 2009-08-12 Univ Southern California ANTI-CANCER POLYIMMUNOTHERAPY IN WHICH CO-STIMULATING MOLECULES ARE USED
SI1877090T1 (sl) 2005-05-06 2014-12-31 Providence Health System Trimerni fuzijski protein OY40-imunoglobulina in postopki uporabe
CA3151350A1 (en) 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
TWI466269B (zh) 2006-07-14 2014-12-21 Semiconductor Energy Lab 非揮發性記憶體
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
JP2010518873A (ja) 2007-02-27 2010-06-03 ジェネンテック， インコーポレイテッド アンタゴニスト抗ｏｘ４０抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
CA2963124C (en) 2007-07-10 2019-10-15 Apogenix Ag Tnf superfamily collectin fusion proteins
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009079335A1 (en) 2007-12-14 2009-06-25 Medarex, Inc. Binding molecules to the human ox40 receptor
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8592557B2 (en) 2008-06-17 2013-11-26 Apogenix Gmbh Multimeric TNF receptor fusion proteins and nucleic acids encoding same
SI2310509T1 (sl) 2008-07-21 2015-07-31 Apogenix Gmbh TNFSF enoverižne molekule
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
DK4209510T5 (da) 2008-12-09 2024-07-22 Hoffmann La Roche Anti-pd-l1-antistoffer og deres anvendelse til at fremme t-cellefunktion
EP2382236B1 (en) 2009-01-09 2016-08-17 Apogenix AG Fusion proteins forming trimers
US8383099B2 (en) * 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
BR112012012465B1 (pt) 2009-11-24 2023-03-14 Medimmune Limited Anticorpo isolado ou fragmento de ligação do mesmo que se liga especificamente a b7-h1 humano, composição compreendendo o mesmo e usos
CA2783550A1 (en) 2009-12-08 2011-06-16 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US9783578B2 (en) 2010-06-25 2017-10-10 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN103221427B (zh) 2010-08-23 2016-08-24 德克萨斯州立大学董事会 抗ox40抗体和使用其的方法
EP2614082B1 (en) 2010-09-09 2018-10-03 Pfizer Inc 4-1bb binding molecules
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CN103517718A (zh) 2010-11-12 2014-01-15 尼克塔治疗公司 Il-2部分与聚合物的缀合物
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
US20140234320A1 (en) 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
BR112013032552A2 (pt) 2011-07-24 2017-12-12 Curetech Ltd variantes de anticorpos monoclonais humanizados imunomoduladores
RU2562874C1 (ru) 2011-08-23 2015-09-10 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Антитела против ох40 и способы их применения
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP3763741A1 (en) 2011-11-28 2021-01-13 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
KR20140142736A (ko) 2012-03-29 2014-12-12 오리진 디스커버리 테크놀로지스 리미티드 인간의 pd1의 bc 루프로부터의 면역조절 사이클릭 화합물
EP3800242A1 (en) 2012-05-18 2021-04-07 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
EP2859093A4 (en) 2012-06-11 2016-08-17 Wolf Wilson Mfg Corp IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
WO2014133567A1 (en) 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
NZ712903A (en) 2013-03-18 2018-07-27 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
WO2014210036A1 (en) 2013-06-24 2014-12-31 Wilson Wolf Manufacturing Corporation Closed system device and methods for gas permeable cell culture process
HUP1300432A2 (hu) 2013-07-10 2015-01-28 Tamas Kardos Downhill kerékpár szerkezet javított felfüggesztéssel
HUE048874T2 (hu) 2013-09-06 2020-08-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazol-származékok, mint immunmodulátorok
KR20160081898A (ko) 2013-09-06 2016-07-08 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
IL296026B2 (en) 2013-09-13 2024-10-01 Beigene Switzerland Gmbh Anti-PD1 antibodies and their uses as drugs and for diagnosis
EP3527587A1 (en) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
TW201613635A (en) 2014-02-04 2016-04-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
US20170107490A1 (en) * 2014-06-11 2017-04-20 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
RS65448B1 (sr) * 2016-10-26 2024-05-31 Iovance Biotherapeutics Inc Restimulacija krioprezerviranih tumor-infiltrirajućih limfocita
TWI788307B (zh) * 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11401507B2 (en) * 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

Also Published As

Publication number Publication date
EP4378530A2 (en) 2024-06-05
EP3843759B8 (en) 2024-03-20
DK3843759T5 (da) 2024-08-19
EP3843759B1 (en) 2024-02-14
AU2019377771A1 (en) 2021-04-15
EP3843759A2 (en) 2021-07-07
DK3843759T3 (da) 2024-05-21
US20240307450A1 (en) 2024-09-19
SG11202101792TA (en) 2021-03-30
JP2021535128A (ja) 2021-12-16
US20220118012A1 (en) 2022-04-21
KR20210053922A (ko) 2021-05-12
EP4378530A3 (en) 2024-08-28
BR112021003491A2 (pt) 2021-05-18
HUE066849T2 (hu) 2024-09-28
WO2020096682A3 (en) 2020-06-25
FI3843759T3 (fi) 2024-05-16
CN112955160A (zh) 2021-06-11
CA3111210A1 (en) 2020-05-14
TW202031273A (zh) 2020-09-01
ES2982415T3 (es) 2024-10-16
MX2021002241A (es) 2021-05-27
PL3843759T3 (pl) 2024-06-17
WO2020096682A2 (en) 2020-05-14
IL281022A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
SG11202104663PA (en) Treatment of nsclc patients refractory for anti-pd-1 antibody
PT3843759T (pt) Utilização de linfócitos infiltrantes de tumores para tratar doentes com nsclc refratário ao anticorpo anti-pd-1
ZA202004735B (en) Anti-pd-1 antibodies and methods of treatment
IL280707A (en) Diagnostic and therapeutic methods for treating breast cancer
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
IL268479A (en) Anti-PD-1 antibodies for the treatment of lung cancer
EP3867410A4 (en) METHODS OF DETERMINING A TREATMENT FOR CANCER PATIENTS
EP3524268A4 (en) USE OF A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND A VEGFR INHIBITOR IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCERS
MX2016014189A (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
HK1247578A1 (zh) 用於治療非小細胞肺癌的組合抗pd-l1和抗ctla4抗體
IL276446A (en) Methods for the selection and design of safer and more effective antibodies against CTLA-4 for cancer treatment
ZA201903105B (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
SG11202007590TA (en) Methods for treating cancer with anti-pd-1 antibodies
IL277861A (en) Antibodies specific to AXL for cancer treatment
GEP20217317B (en) Combination therapy for the treatment of cancer
IL289787A (en) Antibody combinations for cancer treatment in specific patients
IL279353A (en) Use of antibody protein / TGF-beta for the treatment of NSCLC
IL275940A (en) Combined treatment with antibodies against IL-8 and against PD-1 for cancer treatment
IL281439A (en) Combined treatment for blood cancer
IL283064A (en) Pharmaceutical combination of anti-CEACAM6 and anti-PD-1 or anti-PD-L1 antibodies for cancer treatment
IL282313A (en) Abituzumab for the treatment of colorectal cancer
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
IL275981A (en) Combined therapies for the treatment of hepatocellular carcinoma
ZA202107993B (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors
GB201903012D0 (en) Antibodies for treatment of cancer and other diseases